Dashboard
Manage Tickers

IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 2.33 $ 0.07 (3.11 %)    

Monday, 22-Apr-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 418.61 $ 4.17 (1.01 %)
DIA $ 382.46 $ 2.57 (0.68 %)
SPY $ 499.72 $ 4.56 (0.92 %)
TLT $ 89.01 $ -0.15 (-0.17 %)
GLD $ 215.58 $ -5.46 (-2.47 %)
$ 2.32
$ 2.21
$ 0.00 x 0
$ 0.00 x 0
$ 2.21 - $ 2.46
$ 1.50 - $ 3.90
170,667
na
275.46M
$ 0.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immutep-appoints-leading-research-institute-to-conduct-first-in-human-phase-i-study-of-imp761
Immutep Appoints Leading Research Institut...
04/18/2024 12:07:32

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody de...

Core News & Articles
Immutep Announced Tuesday, Positive Feedba...
04/17/2024 09:20:38

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

cancer-focused-immuteps-stock-soars-on-tuesday---heres-why
Cancer Focused Immutep's Stock Soars On Tu...
03/05/2024 20:57:30

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic...

immutep-announces-first-clinical-data-from-90mg-dosing-of-efti
Immutep Announces First Clinical Data From...
03/05/2024 13:12:42

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEn...

immutep-q2-2024-cash-and-cash-equivalent-1037m
Immutep Q2 2024 Cash And Cash Equivalent ~...
01/30/2024 13:14:45

first-patient-dosed-in-trial-evaluating-efti-and-the-anti-pd-l1-therapy-bavencio-in-metastatic-urothelial-cancer
First Patient Dosed In Trial Evaluating Ef...
01/04/2024 13:17:06

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

immutep-limited-announces-constructive-feedback-has-been-received-from-the-paul-ehrlich-institut-regarding-the-planned-tacti-004-phase-iii-trial-of-eftilagimod-alpha-for-first-line-treatment-of-metastatic-non-small-cell-lung-cancer
Immutep Limited Announces Constructive Fee...
12/21/2023 13:04:08

Among the other items discussed at the meeting were general aspects of the trial design, including selection of the control arm...

immutep-receives-a26-million-rd-tax-incentive-from-french-government
Immutep Receives A$2.6 Million R&D Tax Inc...
12/07/2023 13:16:33

 Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing nove...

immutep-secures-a26m-french-rd-tax-incentive
Immutep Secures A$2.6M French R&D Tax Ince...
12/06/2023 21:41:31

immutep-announces-site-expansion-for-insight-003-phase-i-trial
Immutep Announces Site Expansion For INSIG...
11/22/2023 13:03:28

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

immutep-completes-enrollment-in-tacti-003-phase-iib-trial-of-efti-and-keytruda-in-first-line-metastatic-or-recurrent-head-and-neck-squamous-cell-carcinoma
Immutep Completes Enrollment In TACTI-003 ...
11/09/2023 13:02:00

immutep-on-sunday-announced-completion-of-the-safety-lead-in-and-opening-of-the-randomized-phase-ii-of-the-aipac-003-phase-iiiii-trial-in-metastatic-breast-cancer
Immutep On Sunday Announced Completion Of ...
11/06/2023 09:41:49

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

immutep-announces-new-biomarker-data-from-the-tacti-002keynote-798-phase-2-trial-of-eftilagimod-alpha-combined-with-mercks-keytruda-as-first-line-treatment-for-unresectable-or-metastatic-non-small-cell-lung-cancer---8k
Immutep Announces New Biomarker Data From ...
11/03/2023 10:11:22

immutep-quarterly-activities-report-q1-fy24-with-a-cash-and-cash-equivalent-balance-as-at-30-september-2023-of-approximately-1101m
Immutep Quarterly Activities Report Q1 FY2...
10/31/2023 12:07:28

FINANCIAL SUMMARYImmutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24),...

immutep-receives-aud113m-rd-tax-incentive
Immutep Receives ~AUD$1.13M R&D Tax Incentive
10/25/2023 12:19:33

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or the "Company"), is pleased to announce that it has recei...

immutep-received-a113m-rd-tax-incentive
Immutep Received ~A$1.13M R&D Tax Incentive
10/25/2023 08:53:01

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or the "Company"), is pleased to announce that it has recei...

immutep-reports-clinical-data-from-insight-003-trial-at-esmo-congress-2023
Immutep Reports Clinical Data From INSIGHT...
10/24/2023 12:08:59

Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in...

Core News & Articles
Immutep's Efti In Combination With KEYTRUD...
10/23/2023 12:06:04

Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients express...

update-on-new-data-in-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-presented-at-esmo-2023
Update On New Data In First Line Treatment...
10/22/2023 22:48:06

https://www.immutep.com/files/content/investor/presentation/2023/ESMO%20Congress%202023%20TACTI-002%20Webcast%20Presentation%20...

Core News & Articles
Immutep Announced Commercial Manufacturing...
09/21/2023 10:09:50

mmutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)